Amanda Feilding, born Amanda Fielding, is a prominent British drug policy reformer, scientific researcher, and founder of the Beckley Foundation. She was born on April 5, 1943, in England. Feilding has dedicated her life to exploring the potential benefits of psychedelic substances and advocating for evidence-based drug policy reform.
Feilding’s interest in psychedelic research began in the 1960s when she first experimented with LSD (lysergic acid diethylamide). Inspired by her experiences and recognizing the therapeutic potential of psychedelics, she embarked on a mission to challenge the stigma and misinformation surrounding these substances.
In 1998, Feilding established the Beckley Foundation, a non-profit organization focused on advancing global drug policy reform and supporting scientific research into the therapeutic uses of psychedelics. The foundation collaborates with leading researchers, policymakers, and institutions to conduct studies, gather evidence, and promote a rational approach to drug policy.
Feilding has been instrumental in promoting the study of psychedelic substances and their potential benefits in addressing mental health issues. Through the Beckley Foundation, she has supported research on psilocybin (found in “magic mushrooms”), MDMA (commonly known as “ecstasy”), and other psychedelics, exploring their potential in treating conditions such as depression, PTSD, addiction, and anxiety.
In addition to her advocacy and research efforts, Feilding has actively engaged with policymakers and international organizations to influence drug policy reform. She has presented evidence and recommendations based on scientific research to organizations such as the United Nations and the World Health Organization, advocating for more rational, compassionate, and evidence-based drug policies.
Amanda Feilding’s work has played a significant role in shifting the public and scientific perception of psychedelic substances. Her dedication to evidence-based research and drug policy reform has contributed to the growing recognition of psychedelics as valuable tools in mental health treatment. By challenging outdated beliefs and promoting informed dialogue, she has been a driving force in shaping a more progressive and compassionate approach to drug policy.
